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The chemistry, biochemistry, pharmacology and molecular biology of oxylipins (defined as
a family of oxygenated natural products that are formed from unsaturated fatty acids by
pathways involving at least one step of dioxygen-dependent oxidation) are complex and
occasionally contradictory subjects that continue to develop at an extraordinarily rapid
rate. The term includes docosanoids (e.g. protectins, resolvins and maresins, or special-
ized pro-resolving mediators), eicosanoids and octadecanoids and plant oxylipins, which
are derived from either the omega-6 (n-6) or the omega-3 (n-3) families of polyunsaturated
fatty acids. For example, the term eicosanoid is used to embrace those biologically active
lipid mediators that are derived from C20 fatty acids, and include prostaglandins, thrombox-
anes, leukotrienes, hydroxyeicosatetraenoic acids and related oxygenated derivatives. The
key enzymes for the production of prostanoids are prostaglandin endoperoxide H synthases
(cyclo-oxygenases), while lipoxygenases and oxidases of the cytochrome P450 family pro-
duce numerous other metabolites. In plants, the lipoxygenase pathway from C18 polyunsat-
urated fatty acids yields a variety of important products, especially the jasmonates, which
have some comparable structural features and functions. Related oxylipins are produced by
non-enzymic means (isoprostanes), while fatty acid esters of hydroxy fatty acids (FAHFA) are
now being considered together with the oxylipins from a functional perspective. In all king-
doms of life, oxylipins usually act as lipid mediators through specific receptors, have short
half-lives and have functions in innumerable biological contexts.
Introduction
Since the pioneering work of George and Mildred Burr (reviewed in [1]) some 90 years ago, it has been
known that certain fatty acids are essential in human (and most other animal) diets. There are two types
of essential fatty acids (EFAs), which belong to the n-3 (omega-3) and n-6 (omega-6) polyunsaturated
fatty acid (PUFA) families (i.e. the last double bond in these acids is either three or six carbons from the
methyl end of the chain). In the early experiments, fat-free diets were shown to give rise to a variety of
physiological symptoms that could be alleviated by feeding linoleic (LA) andα-linolenic (ALA) acids. The
reason why these fatty acids are essential in the diet is that humans and animals in general do not have the
necessary desaturases (12 and 15) to form them from oleic acid, i.e. to insert a new double bond after
one that is pre-existing [2]. They are produced almost entirely in photosynthetic organisms that evolve
oxygen—such as cyanobacteria, algae, mosses and higher plants. While LA and ALA can be regarded as the
key EFAs of the n-6 and n-3 families, respectively, there may be a need for longer chain PUFAs, produced
from these precursors by sequential elongation and desaturation reactions, for specific functions. Such
acids (e.g. arachidonic (ARA), eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids) are termed
‘conditionally essential’ [3]. Moreover, there has been much recent interest in providing dietary 20 or 22C
PUFAs and also ensuring that the ratio of dietary n-6/n-3 PUFAs is maintained at 3-4, which is much
lower than in many current ‘Western’ diets [4].
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Figure 1. Generation of the classic eicosanoids (taken from [2] with permission)
Polyunsaturated fatty acids are important components of phospholipids in membranes to which they impart desir-
able physical properties. However, a major reason why we need EFA and why they produce so many diverse effects is
because they are metabolised to give rise to lipid signalling molecules [5]. In the main, the latter are 20C (eicosanoids)
or 22C (docosanoids) oxygenated derivatives, collectively termed ‘oxylipins’. Although linoleic acid is an important
constituent of skin lipids [6], where it has vital functions, much of the dietary need for EFAs is to make longer-chain
lipid signalling molecules. Nevertheless, there are a number of important signalling molecules in animals, which are
formed from linoleic acid or α-linolenic acid per se (e.g. octadecanoids) [7].
In this article, we briefly describe the conversion of n-3 and n-6 PUFAs into various classes of lipid mediators. We
also summarise the latter’s biological actions. More details of the metabolism and function of these lipid mediators
will be found in subsequent chapters that cover eicosanoids, isoprostanes, specialised pro-resolving mediators (SPMs),
endocannabinoids and jasmonates.
Conversion of essential fatty acids into eicosanoids
A simplified picture of the generation of classic eicosanoids (derived from the Greek for 20) is shown in Figure 1. Three
different types of oxidation reactions utilise a 20-carbon unesterified fatty acid precursor, such as arachidonic acid
(ARA, the main n-6 precursor) or eicosapentaenoic acid (EPA, the main n-3 precursor). These involve lipoxygenase,
cyclooxygenase and cytochrome P450 oxidase or epoxygenase enzymes [8].
Before reaction occurs, the PUFAs are usually released from membrane phospholipids mainly by phospholipase A2
(PLA2) action. A considerable number of PLA2 enzymes have been characterised and shown to occur in several unre-
lated protein families [9]. Overall, they can be broadly categorised into cytosolic calcium-dependent PLA2 (cPLA2),
cytosolic calcium-independent PLA2 (iPLA2), and secreted PLA2 (sPLA2). The concentration of non-esterified PU-
FAs, such as arachidonic acid, in cells is normally far below the Km of enzymes such as cyclooxygenase (prostaglandin
H2 synthase) so activation of hydrolytic enzymes, especially cPLA2, is a key regulatory reaction. For the 20C PUFAs,
ARA and EPA, different lipid classes contain important relative concentrations. Thus, for ARA, two phosphoglyc-
eride classes are important sources—phosphatidylcholine (the most abundant phosphoglyceride in most mammalian
membranes) and phosphatidylinositol (and its phosphorylated derivatives) by virtue of the high concentration of
ARA at the sn-2 position together with the specificity of cPLA2α [2]. Other potential sources of ARA or EPA are the
plasmalogens but because these lipids are poor substrates for PLA2, they are usually hydrolysed by plasmalogenase
(alkylglycerol monooxygenase) first [10,11].
Release of non-esterified PUFAs from membrane lipids can be enhanced by specific physiological stimulae (e.g.
adrenaline, angiotensin II, certain antibody–antigen complexes) or non-specific pathological conditions. Of the many
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Figure 2. Cyclooxygenase activity (taken from [2] with permission)
lipases that can be activated in this way, cPLA2α appears the most important as it has a marked specificity for phospho-
lipids containing arachidonic acid in the sn-2 position. Hormonally induced mobilisation of Ca2+ leads to the move-
ment of the enzyme from the cytosol to the endoplasmic reticulum and the nuclear envelope. Its activity is increased
by phosphorylation. Two specific lipids—ceramide 1-phosphate and phosphatidylinositol 4,5-bisphosphate—bind to
the enzyme and modify both its activity and its translocation within cells [12].
Secretory PLA2 (sPLA2) is also stimulated by Ca2+ but at the higher concentrations found outside the cell. The
enzyme is rather non-specific towards different phosphoglycerides and towards the fatty acid present at the sn-2
position. There are suggestions that cPLA2 is involved in the rapid response in prostaglandin synthesis while sPLA2
is involved at later stages of prostaglandin stimulation after tissues have been activated further by cytokines, growth
factors or inflammatory factors.
Cyclooxygenase activity
Once the precursor fatty acid (ARA or EPA usually) has been released from membrane lipids, it can be oxidised by
cyclooxygenases (more correctly termed prostaglandin endoperoxide H synthases) [8,13]. Two reactions are catalysed
by a single enzyme—a cyclooxygenase reaction where two molecules of oxygen are added to the substrate and a second
peroxidation (Figure 2). In the case of ARA, prostaglandin PGG2 is the intermediate and PGH2 the first product.
There are two major human cyclooxygenase isoforms, COX-1 and COX-2, which are haemoproteins and act as
homodimers of 576 and 581 amino acids, respectively. COX-1 is constitutively expressed in many mammalian tissues.
It is thought to be responsible for the formation of prostaglandins involved in the general regulation of physiological
events. COX-2, on the other hand, is present at low levels until induced by inflammatory stimuli such as cytokines,
endotoxins, tumour promoters and some lipids. Both isoforms have similar Vmax and Km values for ARA, undergo
suicide inactivation and their reactions can be initiated by hydroperoxide. The COXs will use a broad range of 18
or 20C PUFA substrates although their substrate selectivities are somewhat different. For example, COX-2 needs
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. Prostaglandin precursors and products
lower concentrations of hydroperoxide for activation and has a wider substrate specificity (including those relevant
to endocannabinoid metabolism) than COX-1 [14]. Moreover, COX-2 has a greater capacity to oxidise a number of
PUFAs that are poor substrates for COX-1 including various n-3 PUFAs [14-16]. When acetylated by aspirin, COX-2
in contrast with COX-1 can catalyse a lipoxygenase-type reaction involved, for example, in the formation of various
SPMs (see later). Furthermore, the products of COX reactions will also relate to the balance of substrates available.
Some examples of prostaglandin precursors and their products are shown in Figure 3. The endoperoxide products,
in turn, can form a host of different products (see Figure 4).
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Figure 4. Conversion of cyclooxygenase endoperoxide products to different types of eicosanoids (adapted and re-drawn
from [2])
Cyclooxygenase endoperoxide products can be converted
into various eicosanoids
Three general types of prostanoids can be synthesised from the endoperoxide produced by COX-1 or COX-2 (Figure
4). Prostaglandins PGD2, PDE2 and PGF2 are formed from PGH2, itself produced from ARA [17]. An alternative
prostaglandin, PGI2 (also known as prostacyclin) [18,19] has a distinct function in promoting vasodilation and in-
hibiting platelet aggregation. Together with its action in inhibiting smooth muscle proliferation, PGI2 contributes to
myocardial protection.
Instead of prostacyclin formation, PGH2 can be converted to thromboxane A2 via TxA2 synthase. TxA2 is ex-
tremely labile and rearranges spontaneously with a half-life of approximately 30 s to a stable but physiologically inert
TxB2 (Figure 4). Because TxA2 causes platelet aggregation [20], there have been considerable efforts in searching
for inhibitors of its synthesis. Since TxA2 and PGI2 have antagonistic effects on thrombosis and atherogenesis, it is
obvious that their balance is essential for good cardiovascular health and maintenance of vascular homeostasis [21].
Thus, TxA2 is synthesised mainly in platelets and its production is enhanced during platelet activation to promote
aggregation and vasoconstriction. On the other hand, prostacyclin (PGI2) is the main prostanoid produced by vas-
cular endothelial cells. It will inhibit platelet aggregation and contributes substantially to cardiovascular protection
(see [2,22]).
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Prostanoids have receptors that mediate their actions
In the last two decades, several prostanoid receptors have been identified and partly characterised [23–25]. For
prostaglandins, ten receptors have been characterised. In the case of PGE2, four receptors (EP1–4) have been iden-
tified and each has a different mechanism of action. Other receptors have been identified for PGD2, PGF2α, PGI2
and TxA2. The receptors have seven transmembrane segments and belong to the G protein-coupled receptor (GPCR)
family which constitute the largest family of receptors in humans (approximately 800 coded in the human genome).
Apart from prostanoids [26], receptors have been identified for other lipid mediators [27]. For example, in the case
of leukotrienes, LTB4 has BLT1 (high affinity) and BLT2 (low affinity and less specific) receptors while the cysteinyl
leukotrienes have five (CysLT1, CysLT2, P2Y12, GPR17 and GPR99). Lipoxin [28] and SPMs [29] also have identified
receptors.
By using knockout mice, precise functional roles for the individual receptors are being elucidated.
Prostanoids are produced in situ and are rapidly catabolised
The prostanoids can be regarded as ‘local hormones’. They are produced within tissues and have their main actions
in that locality. In general, prostanoids have very short half-lives in vivo. For example, PGE2 and PGF2α are rapidly
metabolised and do not survive a single pass through the circulation! The lung plays a major role in the catabolism
with oxidation of the hydroxyl group at C15 being the usual target. This is followed by attack of the 13-double bond
and then beta- and omega-oxidation. For the major active prostaglandins, their blood concentrations are less than
10−10 M, emphasising their activity as local hormones (or autocoids). Moreover, unlike conventional hormones, they
are produced in almost every cell in the body. The prostanoids are transported out of cells via carrier-mediated mech-
anisms and, once in the circulation, are deactivated rapidly [2,8].
Aspirin and non-steroidal anti-inflammatory drugs
Aspirin (acetylsalicylic acid) was originally utilised as a substitute for salicylate medicines which had been used for
their health properties for 3,500 years [30,31]. Since 1897, when Bayer produced it, aspirin has been one of the World’s
most commonly used medicines (approximately 40,000 tonnes or up to 120 billion pills per year!).
Of the various non-steroidal anti-inflammatory drugs (NSAIDs) (e.g. aspirin, ibuprofen, indomethacin, di-
clofenac), aspirin is the best known. NSAIDs will compete with PUFA substrates for the reaction site of COX enzymes
but, in general, the therapeutic anti-inflammatory action of NSAIDs is caused by inhibition of COX-2. In contrast,
the simultaneous inhibition of COX-1 causes most of the unwanted side-effects, such as gastric ulceration [32]. Once
bound to the COX-1 active site, aspirin will cause irreversible inactivation through acetylation of serine 530. For
COX-2, the acetylation reaction still allows oxygenation of ARA, in a similar manner to that of a lipoxygenase, but
prostaglandin PGH2 is not formed (see section on resolvins).
Unlike aspirin, most of the other NSAIDs cause reversible inhibition of COX and compete with substrates such
as ARA. Because NSAIDs inhibit both COX enzymes and it would be much more useful to only inhibit COX-2,
considerable effort has been devoted to finding selective inhibitors [32,33]. Some success was achieved initially [34],
but such compounds caused unwanted cardiovascular effects [35], which led to the clinical withdrawal of the initial
products.
Lipoxygenase activity will produce hydroxy-eicosatetraenes,
leukotrienes and other signalling molecules
Lipoxygenases can catalyse three different types of reactions (dioxygenation of lipids to give hydroperoxides; hy-
droperoxidation of the latter into keto lipids; formation of epoxy leukotrienes via leukotriene synthase reaction) due
to their multifunctional nature. Several lipoxygenases (LOXs) occur in mammals and, in humans, six main family
members have been listed—5-LOX, 12-LOX, 12/15-LOX (15-LOX type 1), 15-LOX type 2, 12R-LOX and epidermal
LOX [36]. There are seven LOXs in mice. Orthologues of the same gene have different reaction selectivities in differ-
ent species. This can often compromise extrapolation of data from animal experiments to human conditions. Each of
the lipoxygenase proteins in animals has a single polypeptide chain of 75–80 kDa mass. The N-terminal ‘beta-barrel’
domain functions in substrate acquisition while a larger catalytic domain has a single non-heme iron atom which is
bound to conserved histidine residues and to the carboxyl group of a conserved isoleucine at the C-terminus of the
enzyme. The iron is active in the ferric state. For 5-LOX and 8-LOX activities the substrate ARA enters carboxyl group
first while for 12-LOX or 15-LOX the methyl terminus enters the active site. While the PUFA substrate is held in a
tight channel, smaller channels direct molecular oxygen towards the selected carbon to allow formation of specific
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Figure 5. Leukotriene biosynthesis
hydroperoxy-eicosatetraenes (HPETEs), which are subsequently reduced to hydroxy-eicosatetraenes (HETEs). Each
lipoxygenase acts with high regio- and stereo-specificity to produce HETE with distinctive biological functions in
particular tissues.
For formation of leukotrienes, 5-LOX is the key enzyme [37,38]. As for prostanoids, a non-esterified (free)
fatty acid is the substrate. A two-step concerted reaction begins leukotriene formation (Figure 5) [8]. The first
step is a dioxygenation of C5 to create, in the case of ARA, 5S-hydroperoxy-6t,8c,11c,14c-eicosatetraenoic acid
(5-HPETE). For the second step, two accessory proteins are needed. These are the 5-lipoxygenase activating pro-
tein (FLAP) and coactosin-like protein (CLP). With the aid of these two proteins, 5-LOX converts 5-HPETE into 5,
6-epoxy-7t,9t,11c,14c-eicosatetraenoic acid (5-HETE) or leukotriene A4 (LTA4) (Figure 5).
The unstable LTA4 appears to have little biological function on its own but can be metabolised in two ways to
yield physiologically important leukotrienes. First, it can be hydrolysed by LTA4 hydrolase, a zinc metalloprotein,
to form the dihydroxy acid LTB4 [39]. Secondly, LTA4 is converted to a ‘cysteinyl leukotriene’ by the addition of
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 6. Examples of lipoxin biosynthesis
gamma-glutamyl-cysteinyl glycine and with the assistance of FLAP, this yields LTC4 which can be reacted with a
transpeptidase to remove glutamate and yield LTD4. Finally, a dipeptidase forms the final ‘cysteinyl leukotriene’ LTE4.
The leukotrienes have a variety of important biological effects [40]. LTB4 is a potent chemotactic agent and is one
of the first signals that attract innate immune cells such as leukocytes to the site of insult. In contrast, LTB5 (which
is formed from EPA) strongly inhibits the pro-inflammatory actions of LTB4. Leukotriene LTC4, together with other
‘cysteinyl leukotrienes’ (LTD4, LTE4) are the slow-acting substances of anaphylaxis, originally reported nearly 100
years ago. These lipid mediators exert a range of pro-inflammatory actions including constriction of airways and
vascular smooth muscles. LTD4 and LTE4 are overexpressed in several types of cancer and are considered tumorigenic.
Instead of leukotrienes, ARA can form lipoxins, which are trihydroxy-eicosatetraenoic acids where the four dou-
ble bonds are in conjugation (LXA4, LXB4) [41]. These are considered one of a group of specialised pro-resolving
mediators (SPMs) which include resolvins, protectins and maresins (see later). Oxidation of ARA needs two differ-
ent types of lipoxygenase in this case (see an example in Figure 6), and as few cell types have both of the necessary
lipoxygenases, the synthesis of lipoxins needs trans-cellular pathways [42]. In such pathways, because a single cell
lacks all of the enzymes necessary for a metabolic sequence, it has to combine with another cell type to complete a
particular conversion. Of course, such cellular interactions need appropriate transport mechanism(s) associated with
the pathway.
Two other minor classes of lipoxygenase products are the eoxins and the hepoxilins. Eoxins are related to the
cysteinyl-leukotrienes and are products of the 12/15-LOX in human eosinophils and mast cells. They are potent
pro-inflammatory agents [43]. Hepoxilins are especially important in human epidermis [44,45] and are made in one
of two pathways involving 12-LOX. Compounds analogous to those formed from ARA can be produced from EPA
or DHA and, in skin, linoleate is an important substrate [46].
Cytochrome P450 oxidases, HETEs and
epoxyeicosatetraenoic acids
In addition to cyclooxygenase or lipoxygenase activity, a third oxygenation of relevant PUFAs involves cytochrome
P450 oxidases (Figure 1) [8,47,48]. These enzymes are membrane-bound hemoproteins that transfer a single oxygen
to the substrate carbon i.e. they are monooxygenases which produce water as a second product. NADPH is also needed
and the transfer of electrons requires a NADPH-cytochrome P450 reductase. Various cytochrome P450 oxidases can
produce a mixture of hydroxy-eicosatetraenes (HETEs) (Figure 7). The balance of HETEs generated depends on the
tissue, cell type and the catalytic efficiency of the individual cytochrome P450 oxidase isoforms [49]. In addition
408 © 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
Essays in Biochemistry (2020) 64 401–421
https://doi.org/10.1042/EBC20190082
Figure 7. Metabolism of arachidonic acid by the cytochrome P450 epoxygenase pathway (taken from [2] with permission)
to their function in generating HETE isomers, the cytochrome P450 oxidases have other important roles in lipid
metabolism [50].
For ARA, three types of reaction can occur. First, a series of HETE products can be formed with cis-trans conju-
gated diols containing a hydroxyl group at one of six positions (5, 8, 9, 11, 12 or 15). Second, omega or omega-1 hy-
droxylases introduce a hydroxyl group at carbons 20 or 19, respectively, although minor activities with other oxidases
can produce 16, 17 or 18 hydroxyl products. 20-HETE is pro-inflammatory and has largely detrimental functions, for
example in increasing hypertension, in promoting systemic vasoconstriction and in tumour growth. It regulates vas-
cular smooth muscle and endothelial cells by influencing their proliferation, migration, survival, and tube formation,
acting via a specific G protein receptor (GPR75).
Third, cytochrome P450 oxidases can form a series of cis-epoxyeicosatrienoic acids (EETs) (14,15-, 11,12-, 8,9-
and 5,6-EETs). Depending on the cytochrome 450 oxidase isoform, different EETs may predominate although most
enzymes can produce all four isomers. The various EETs have major functions as autocrine and paracrine effectors
in the cardiovascular and renal systems, which are believed to be largely beneficial. Because of the anti-hypertensive,
fibrinolytic and anti-thrombotic properties of EETs, their presence in red blood cells has important implications for
the control of circulation and the physical properties of the circulating blood. Both cis- and trans-EETs are synthesised
and stored in erythrocytes, and they are produced and released in response to a low oxygen concentration as during
exercise, for example.
EETs are rapidly metabolised in vivo to the corresponding dihydroxyeicosatrienoic acids (DHETs). This involves
epoxide hydrolases, of which there are two isoforms, one membrane-bound and one soluble. The DHETs formed
were once assumed to be inactivation products but now seem to have some biological activity of their own.
Historically, much of the original research with cytochrome P450 oxidases (as with cyclooxygenases and lipoxy-
genases) has focussed on ARA [48]. However, they have important activities with n-3 PUFAs such as EPA and DHA
(Figure 8). In fact, the latter PUFAs are often the preferred substrates for some of the cytochrome P450 oxidases.
Since their products often compete with metabolites from ARA, they can have beneficial effects, e.g. in alleviating
pain. Such functions may account for some of the advantages of consuming significant dietary n-3 PUFAs. In addi-
tion, hydroxyoctadecadienoic acids (octadecanoids), which are formed by oxidation of linoleic acid, have a role in
inflammation associated with important diseases, such as metabolic syndrome and cancer [7].
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 8. Action of CYP450 oxidases on EPA and DHA (taken from [2] with permission)
Figure 9. Examples of specialised pro-resolving mediators (SPMs)
Specialised pro-resolving mediators
Specialised pro-resolving mediators (SPMs), so-called because of their intimate involvement in the resolution stage of
inflammation, have been mentioned already when discussing lipoxins in connection with lipoxygenase action. Over
the last 15 years there has been increasing interest in the discovery and, subsequently, elucidation of the biosynthesis
and biological function of other SPMs—protectins, resolvins and maresins [51]. In contrast with lipoxins, which are
formed from the n-6 PUFA ARA, these other three groups of lipid mediators have very long chain n-3 PUFAs as
their precursors, i.e. EPA, n-3 docosapentaenoic acid (DPA) and DHA. Oxylipins derived from EPA are designated
SPMs of the E series while those from DHA are SPMs of the D series (Figure 9). An overall picture of the formation of
protectins, resolvins and maresins by dioxygen-dependent oxidation is shown in Figure 10, and it will be seen that the
same three types of oxidising enzymes discussed previously are all involved but with a preponderance of lipoxygenase
reactions.
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Figure 10. Biosynthesis of SPMs
Protectins
When studies were first made of metabolite formation from DHA in brain tissue following aspirin treatment, new
docosanoids were discovered. These were dihydroxylated E,E,Z-docosatrienes and were termed ‘neuroprotectins’
because of their protective action and their formation in nervous tissue such as brain [52] where DHA is a major
fatty acid [53,54]. Since then, similar docosanoids have been found in many tissues so ‘protectins’ is the preferred
nomenclature [55,56].
The biosynthetic pathway to protectin D1 (PD1, previously neuroprotection D1 or NPD1) is shown in Figure 11.
Oxidation by 15-LOX yields a 17S-hydroperoxy-DHA that is converted into an epoxide and then hydrolysed. All
the intermediates have very precise stereochemistry, which is also necessary for the biological activity of PD1. As
illustrated in Figure 11, alternative reactions are possible via 5-LOX or non-enzymatic hydrolysis and these yield
products which also have significant biological activity. Of interest is the reaction of 5-LOX which, when uncoupled
from FLAP produces the SPM mediator (10S,17S-dihydroxy-DHA) rather than the inflammatory leukotriene B4.
In addition to DHA, both 22:5(n-3) and 22:5(n-6) are good substrates for the 15-LOX. Their products as well as an
omega-hydroxy analogue of PD1 (produced by CYP1) are all potent anti-inflammatory compounds.
Aspirin-triggered protectins
Instead of the 17S intermediate produced by 15-LOX (Figure 11) in the production of PD1, aspirin treatment allows
production of the 17R epimer (i.e. 10R,17R-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid) from DHA.
As mentioned before, aspirin is a classic inhibitor of COXs when it acetylates the active site. However, whereas it
irreversibly inhibits COX-1, it only partially blocks the active site of COX-2, which retains lipoxygenase activity similar
to that of 15-LOX but with the oxygen insertion in the R- rather than the S-configuration. With ARA as substrate the
15R-HETE is converted into lipoxins. The latter was the first type of lipid mediator known to start the resolution of
inflammation. Thus, low-dose aspirin treatment will start resolution earlier than might be so otherwise (see chapter
on ‘Specialised Pro-resolving Mediator Network’). Because most NSAIDs inhibit COXs reversibly, their use can delay
complete resolution of inflammation.
Resolvins
Resolvins (resolution phase interaction products) are produced from EPA, DPA and DHA and stop inflammation
becoming chronic and, hence, prevent tissue damage and reduce the risk of a host of diseases arising [51,57]. COX-2
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 11. Biosynthesis of protectin D1
Figure 12. Biosynthesis of E-series resolvins
which has been acetylated by aspirin or a CYP 450 will introduce an 18R-hydroperoxy group into the EPA molecule
(Figure 12). Reduction yields RvE2 while two steps are used for RvE1 formation. Since it is rare for all the enzymes
needed to be found in a single cell, a trans-cellular sequence is needed as in the formation of lipoxins. Instead of EPA,
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Figure 13. Aspirin-triggered resolvins
DHA can be converted into 17R-resolvins by a similar aspirin-triggered COX-2 mechanism. The aspirin-triggered
resolvins AT-RvD1 and AT-RvD2 (Figure 13) are formed when epoxidation takes place on 17R-hydroperoxy inter-
mediate while a 5-LOX reaction with FLAP assistance forms AT-RvD3 or AT-RvD4.
Epimeric 18S-resolvins are also produced in vivo by related pathways with 15-LOX catalysing the first step (c.f.
protectin formation) and these S-resolvins have their own distinct biological activities. Thus, in the absence of aspirin,
15-LOX generates 17S-hydroxyDHA which then goes on to form RvD1 and epimeric RvD2, both of which contain
a 17S-hydroxyl group. A different intermediate from 17S-hydroxyDHA is transformed via an epoxide to RvD3 and
RvD4. Both the products and intermediates from DHA have anti-inflammatory properties and two more resolvins,
RvD5 and RvD6, have now been characterised.
In addition to EPA and DHA, DPA has been shown to be converted to three resolvins of which RvD1(n-3DPA) is the
most abundant. Four further metabolites of DPA have a hydroxyl group at the 13-position and have been designated
as 13-series resolvins (RvTs).
Tissue inactivation of resolvins has been studied best in the case of RvE1 and RVD1 where oxidation is key. For
RvE1, at least four distinct oxidative pathways are involved.
Maresins
A single oxygenation by 12-LOX (in macrophages or platelets) to form a 14S-hydroperoxyDHA intermediate
begins the formation of maresins (macrophage mediator in resolving inflammation) as illustrated in Figure 14
[58,59]. Some details of the pathway are still ill-defined but both MaR1 and MaR2 have potent anti-inflammatory
and pro-resolving activities. Similar oxygenated compounds with anti-inflammatory properties are formed from
22:5(n-3) and 22:5(n-6) fatty acids.
Some maresin-like di-oxygenated metabolites produced by sequential oxidation by 12-LOX and en-
zymes of the CYP450 family can occur in macrophages. For example, 14S, 21S-dihydroxy-docosa-
4Z,7Z,10Z,12E,16Z,19Z-hexaenoic acid and its epimers can be produced. This compound is induced by wounding
and has been shown to promote wound healing. Similar 14, 22-dihydroxy metabolites are synthesised in leukocytes
and platelets and also promote wound healing.
Sulphido-peptide conjugated mediators (analogous to cysteinyl-leukotrienes) have been detected for the SPMs in
macrophages, initially for maresins and then for protectins and resolvins [51]. The various compounds have been
detected in lymph nodes, serum and milk in humans and shown to regulate bacterial clearance and the repair and
regeneration of damaged tissues.
Biological activities of SPMs
Given the diverse nature of SPMs, it is hardly surprising that they can give rise to a variety of biological effects. In
general, their action is via specific G-protein coupled receptors which can lead to both rapid and long-term actions.
Moreover, SPMs can antagonise pro-inflammatory receptors such as the leukotriene B4 receptor, BLT1.
As mentioned before, acute inflammation is a vital response to infection or tissue damage. However, the time scale
needs to be kept as short as needed and chronic inflammation avoided. Indeed, occurrence of the latter will lead almost
inevitably to tissue damage and loss of function. Under normal circumstances compounds involved in inflammation
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Figure 14. Biosynthesis of maresins
may initiate the resolution phase. For example, leukotriene LTB4 and prostaglandins, PGE2 and PGD2, will stimulate
induction of 15-LOXs needed for later production of SPMs.
Early in inflammation there is a change in ARA metabolism from synthesis of leukotrienes to lipoxin formation.
Local mobilisation of n-3 PUFAs, such as DHA, occurs followed by production of SPMs. As such mediators are
formed, macrophages and mast cells remove excess neutrophils together with cell debris resulting from microorgan-
isms and host defences. A noted ancillary effect is that low dose aspirin facilitates the resolution of inflammation by
enhancing conversion of EPA and DHA to resolvins of the E and D series.
While the resolution process is on-going, a change in the phenotype of macrophages towards a pro-resolution
state occurs. Initially, at the onset of inflammation, macrophages counter disease by removing invading pathogens by
phagocytosis. However, these actions can cause trauma and tissue damage so SPMs, like lipoxins, have an important
role in regulating and inhibiting these effects. Thus, RvE1 dramatically reduces dermal inflammation, peritonitis and
interleukin production. A measure of its effectiveness is that it reduces inflammatory pain better than morphine!
Furthermore, RvE2 has been shown to effectively reduce joint pain in arthritis. Similar beneficial effects of resolvins
from DHA have been found (RvD2 ameliorating bacterial sepsis, RvD3 active in later stages of resolution, RvD4
helping clearance of apoptotic cells by skin fibroblasts).
The protectins have similar effects to resolvins but mainly in brain tissue [60–62]. They promote resolution of
neuroinflammation and stimulate nerve regeneration. In animal models. PD1 has protective effects against stroke
and Alzheimer’s disease. In non-neuronal tissues, PD1 promotes apoptosis of T cells, is beneficial towards asthma and
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may have potential in slowing viral replication. Protectins synthesised in white adipose tissue have anti-inflammatory
effects on obesity and diabetes.
Maresin 1 is a powerful regulator of the resolution of inflammation, tissue regeneration and pain [62]. Notable
effects are in lung, with vascular and metabolic diseases and bacterial infections. Maresins have been found especially
important in tissue regeneration and wound healing in the latter stages of resolution. Indeed, they have been used
successfully for specific surgical interventions.
Although SPMs are produced locally, they also reach the circulation and, therefore, may have effects in tissues
other than where they are synthesised. Notably, SPMs have been found in bioactive concentrations in human milk
and placenta. So, they may function in normal physiological development.
We have already highlighted the importance of SPMs in preventing chronic inflammatory diseases [63,64]. As a
result of basic scientific knowledge, SPMs have been tested in a wide range of experimental models including peritoni-
tis, colitis, arthritis, psoriasis, dry eye, cardiovascular disease, asthma and some cancers (see [65]). Although further
clinical trials are necessary, it is hoped that the use of SPMs may be efficacious for many low-level inflammatory
diseases. Particular attention is being paid to obesity [66], including insulin resistance, Type 2 diabetes, metabolic
disease [67,68], non-alcoholic liver disease and cardiovascular complaints [69]. Overall, treatment of patients with a
diet containing increased levels of very long chain n-3 PUFAs, together with low-dose aspirin may be a cost-effective
method to ameliorate the clinical symptoms of many important disorders where inflammation is involved.
Other oxidised lipids with biological activities
In recent years, it has become apparent that various other oxidised lipids can be formed by both enzymatic and
non-enzymatic means. For example, isoprostanes, neuroprostanes and phytoprostanes [70] are covered in a later
chapter. Enzymatically oxidised phospholipids can be produced by reactions in which eicosanoids are attached in
immune cells. Such lipids are represented by various chemically distinct families with important bioactivities. Lipoxy-
genase activities are usually involved in the formation of these oxidised phospholipids [71–73] which have important
regulatory roles in both health and disease. For example, they have been implicated in ferroptosis, apoptosis, blood
clotting, arthritis, diabetes and cardiovascular disease [74].
Production of VLCPUFAs from dietary essential fatty acids
The VLCPUFAs (>18C) which are almost the exclusive source of the lipid mediators discussed above are not pro-
duced in higher plants [75,76]. Instead, the vast majority are synthesised by marine microalgae at the base of the
marine food web [77]. Nevertheless, even this supply is currently under threat due to climate change [4,78]. For hu-
mans, the precursor essential fatty acids (LA, ALA) can be converted to 20 and 22C PUFA but rather inefficiently
[3,54]. Thus, a dietary supply of EPA and DHA is considered necessary (‘conditionally essential’) under certain cir-
cumstances [3] and, indeed, is considered desirable for all individuals, but especially for the newborn [79–82].
The essential fatty acids, LA and ALA are produced in photosynthetic organisms by specific desaturase enzymes
(e.g. FAD3 and FAD7/8 for ALA). Then a series of desaturation and elongation reactions will convert LA to ARA or
ALA to EPA and then DHA in both humans and fish (the usual source of VLCPUFA in our diets) (Figure 15). The
most direct route to convert EPA to DHA is via an elongation to 22:5 and a 4-desaturase. However, 4-desaturase
activity could not be detected in mammalian tissues and so the ‘Sprecher pathway’ involving a 24:6 intermediate
followed by beta-oxidation was proposed (see [83]). A recent article has suggested a re-visiting of the situation [84]
but, nevertheless, the Sprecher pathway seems to be key in humans and, with the exception of a few teleost species, in
fish also [85]. Thus, because fish are the main dietary source of n-3 VLCPUFA for humans, it is important that they
contain adequate levels of EPA and DHA, and oily fish sources should be from capture fisheries or from aquaculture
with an adequate supply of n-3 VLCPUFA in the feed. Since aquaculture now supplies more than half the fish used
[86] and some 75% of marine-sourced fish oils are currently used in aquaculture [87], it is easy to see that there is
currently a serious problem that will only get worse as demand for EPA and DHA increases in the future [88].
For the conversion of LA and ALA into VLCPUFA, the same enzymes operate for both the n-3 and n-6 pathways
(Figure 15). This means that the dietary ratio of n-6/n-3 PUFAs (mainly LA/ALA) in human diets is important. While
many ‘Western diets’ have a ratio of over 10, for good health a ratio of 3-4 is recommended [4,54,77]. Furthermore,
for some teleost fish the lack of a 5-desaturase means that conversion of ALA to EPA is not possible [89]. It should
also be noted that expression of the necessary enzymes for VLCPUFA biosynthesis in fish is controlled by the diet
[90].
In view of the problems faced in maintaining levels of EPA and DHA in fish being consumed by humans, alternative
sources of these acids for aquaculture or, indeed, directly for human consumption have been sought. Thus, crops
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Figure 15. Conversion of the essential fatty acids to 20- or 22-carbon PUFAs (re-drawn from [90] with permission)
have been manipulated to allow the biosynthesis of EPA and/or DHA [88,91]. Two methods have been used. First, a
polyketide synthase system was used to engineer oilseed rape to yield DHA [92]. This strategy mimicked the enzyme
used by Schizochytrium to make the commercially successful oils used for infant formulations [93]. Second, various
combinations of genes (mostly from microalgae) have been used to allow different higher plant systems to make EPA
and/or DHA [94,95]. The success of these efforts in oilseed crops, especially oilseed rape (Canola) has been discussed
[88]. Currently, there are a number of commercially available (or potentially available) new sources of EPA and DHA
(see [88]).
As has been discussed before, adequate dietary n-3 VLCPUFAs has important implications for good health [96]
and in the prevention of important complaints and illnesses [54,97–99]. These considerations will ensure that supply
of the direct precursors (ARA, EPA, DHA) for lipid mediators will remain an important topic for years to come.
Plant oxylipins
In plants LA and, especially, ALA give rise to bioactive molecules which are very important for functions such as in
stress responses and development [100]. The ‘lipoxygenase pathway ‘is initiated by lipoxygenase (9-LOX or 13-LOX)
attack on a PUFA which, in leaves, is mainly ALA. LOX enzymes in plants are stable proteins, often present in high
amounts, especially in leaves.
The fatty acid hydroperoxides that are produced by plant LOXs can, themselves, be metabolised to yield three
types of derivatives. By a co-oxidation with peroxidase they can form a mixture of epoxy and hydroxy fatty acids
that have roles in cutin formation. In contrast, the hydroperoxides can be cleaved by hydroperoxide lyase to give an
aldehyde and an oxo-unsaturated fatty acid. The emission of C6 aldehydes and alcohols occurs rapidly in plants in
response to wounding, and they contribute to protection against the invasion of fungi and insects, while taking part in
abiotic stress responses by inducing the expression of stress-associated genes.The third reaction with hydroperoxides
is by allene oxide synthase. This forms 12-oxophytodienoic acid which is the precursor for jasmonic acid and other
jasmonates (with intriguing structural similarities to the cyclopentenone prostaglandins). These important effectors
of growth, development and senescence are described in detail in a later chapter (‘Jasmonates’). Some recent updates
on jasmonate functions can be found in a special edition of Plant and Cell Physiology [101–106].
Fatty acid esters of hydroxy fatty acids (FAHFA)
A range of unesterified fatty acids containing a hydroxyl group to which a further fatty acid is esterified have
been found in the adipose tissue, serum, milk and many other tissues of mice and humans. These include several
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regio-isomers of the hydroxyl component as well as many different ester-linked fatty acids [107]. While little is yet
known of the biosynthesis of these lipids, it has been established that they are produced endogenously with defined
stereochemistry, i.e. the hydroxyl group has the R-configuration and peroxisomal enzymes are believed to be involved.
Adipose tissue triacylglycerols act as a reservoir for these compounds, which have been classed as lipokines, i.e. lipid
molecules derived from adipose tissue that act as hormonal regulators and coordinate an array of cellular processes.
Among those biological activities described to date, FAHFA have anti-diabetic and anti-inflammatory effects, even
when administered orally and they protect against colitis by regulating gut innate and adaptive immune responses.
They are believed to have an important role in maintaining normal blood sugar levels and insulin sensitivity, possibly
by acting as selective agonists for the GPR40 and GPR120 receptors [108].
FAHFA have recently been reported in plants also [108] and have been comprehensively reviewed recently [109].
Summary
• Oxylipins, formed from n-3 and n-6 polyunsaturated fatty acids, are important lipid mediators.
• Three types of oxidase (cyclooxygenases, lipoxygenases, cytochrome P450 oxidases) are involved
in their formation.
• Oxylipins bind to receptors, are rapidly catabolised and usually act where they are produced—-as
‘local’ hormones.
• Oxylipins have multiple functions in mammalian health and disease, as well as in other animals
and plants.
Competing Interests
The authors declare that there are no competing interests associated with the manuscript.
Open Access
Open access for this article was enabled by the participation of Cardiff University in an all-inclusive Read & Publish pilot with Port-
land Press and the Biochemical Society under a transformative agreement with JISC.
Author Contribution
This is a joint publication, J.H and W.C equally contributed to the text and created the figures.
Abbreviations
ALA, α-linolenic; ARA, arachidonic; DHA, docosahexaenoic; EFA, essential fatty acid; EPA, eicosapentaenoic; FAHFA, fatty
acid esters of hydroxy fatty acids; LA, linoleic; PUFA, polyunsaturated fatty acid; SPM, specialised pro-resolving mediator.
References
1 Spector, A. and Kim, H.-Y. (2015) Discovery of essential fatty acids. J. Lipid Res. 56, 11–21, https://doi.org/10.1194/jlr.R055095
2 Gurr, M.I., Harwood, J.L., Frayn, K.N., Murphy, D.J. and Michell, R.H. (2016) Lipids: biochemistry, biotechnology and health, 6th edn, Wiley/Blackwell,
Oxford
3 Cunnane, S.C. (2003) Problems with essential fatty acids: time for a new paradigm? Prog. Lipid Res. 42, 544–568,
https://doi.org/10.1016/S0163-7827(03)00038-9
4 Harwood, J.L. (2019) Algae: critical sources of very long-chain polyunsaturated fatty acids. Biomolecules 9, 708,
https://doi.org/10.3390/biom9110708
5 Samuelsson, B. (2012) Role of basic science in the development of new medicines: examples from the eicosanoid field. J. Biol. Chem. 287,
10070–10080, https://doi.org/10.1074/jbc.X112.351437
6 Kendal, A.C., Kiezel-Tsugunova, M., Brownbridge, L.C., Harwood, J.L. and Nicolaou, A. (2017) Lipid functions in skin: differential effects of n-3
polyunsaturated fatty acids on cutaneous ceramides in a human skin organ culture model. Biochim. Biophys. Acta 1859, 1679–1689,
https://doi.org/10.1016/j.bbamem.2017.03.016
7 Vangaveti, V.N., Jansen, H., Kennedy, R.L. and Malabu, U.H. (2016) Hydroxyoctadecadienoic acids: oxidised derivatives of linoleic acid and their role in
inflammation associated with metabolic syndrome and cancer. Eur. J. Pharmacol. 785, 70–76, https://doi.org/10.1016/j.ejphar.2015.03.096
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY).
417
Essays in Biochemistry (2020) 64 401–421
https://doi.org/10.1042/EBC20190082
8 Smith, M.L. and Murphy, R.C. (2016) The eicosanoids: cyclooxygenase, lipoxygenase and epoxygenase pathways. In Biochemistry of Lipids,
Lipoproteins and Membranes, 6th edn., (Ridgeway, N.D. and McLeod, R.S., eds), pp. 260–296, Elsevier, Amsterdam
9 Dennis, E.A., Cao, J., Hsu, Y.H., Magrioti, V. and Kokotos, G. (2011) Phospholipase A2 enzymes: physical structure, biological function, disease
implication, chemical inhibition and therapeutic interventions. Chem. Rev. 111, 6130–6185, https://doi.org/10.1021/cr200085w
10 Dorman, R.V., Toews, A.D. and Horrocks, L.A. (1977) Plasmalogenase activities in neuronal perikarya, astroglia and oligodendroglia isolated from
bovine brain. J. Lipid Res. 18, 115–117
11 Jenkins, C.M., Yang, K., Liu, G., Moon, S.H., Dilthey, B.G. and Gross, R.W. (2018) Cytochrome c is an oxidative stress-activated plasmalogenase that
cleaves plasmenylcholine and plasmenylethanolamine at the sn-1 vinyl ether linkage. J. Biol. Chem. 293, 8693–8709,
https://doi.org/10.1074/jbc.RA117.001629
12 Leslie, C.C. (2015) Cytosolic phospholipase A2; physiological function and role in disease. J. Lipid Res. 56, 1386–1402,
https://doi.org/10.1194/jlr.R057588
13 Smith, W.L., Urade, Y. and Jakobsson, P.-J. (2011) Enzymes of the cyclooxygenase pathways of prostaglandin biosynthesis. Chem. Rev. 111,
5821–5865, https://doi.org/10.1021/cr2002992
14 Rouzer, C.A. and Marnett, L.J. (2009) Cyclooxygenases: structural and functional insights. J. Lipid Res. 50, S29–S34,
https://doi.org/10.1194/jlr.R800042-JLR200
15 Laneuville, O., Breuer, D.K., Xu, N., Huang, Z.H., Gage, D.A., Watson, J.T. et al. (1995) Fatty acid substrate specificities of human
prostaglandin-endoperoxide H synthase-1 and -2. J. Biol. Chem. 270, 19330–19336, https://doi.org/10.1074/jbc.270.33.19330
16 Smith, W.L. and Langenbach, R. (2001) Why are there two cyclooxygenase isozymes? J.Clin. Invest. 107, 1491–1495,
https://doi.org/10.1172/JCI13271
17 Seo, M.-J. and Oh, D.-K. (2017) Prostaglandin synthases; molecular characterization and involvement in prostaglandin biosynthesis. Prog. Lipid Res.
66, 50–68, https://doi.org/10.1016/j.plipres.2017.04.003
18 Stritham, J., Midgett, C., Martin, K.A. and Hwa, J. (2011) Prostacyclin: an inflammatory paradox. Front. Pharmacol. 2, 24
19 Pluchart, H., Khouri, C., Blaise, S., Roustit, M. and Cracowski, J.-L. (2017) Targeting the prostacyclin pathway: beyond pulmonary arterial
hypertension. Trends Pharm. Sci. 38, 512–523, https://doi.org/10.1016/j.tips.2017.03.003
20 Paul, B.Z.S., Jin, J. and Kunapuli, S.P. (1999) Molecular mechanism of thromboxane A2-induced platelet aggregation. J. Biol. Chem. 274,
29108–29114, https://doi.org/10.1074/jbc.274.41.29108
21 Smyth, E.M. (2010) Thromboxane and the thromboxane receptor in cardiovascular disease. Clin. Lipidol. 5, 209–219,
https://doi.org/10.2217/clp.10.11
22 Mitchell, J.A. and Kirkby, N.S. (2019) Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Brit. J. Pharm. 176, 1038–1050,
https://doi.org/10.1111/bph.14167
23 Hirata, T. and Narumiya, S. (2011) Prostanoid receptors. Chem. Rev. 111, 6209–6230, https://doi.org/10.1021/cr200010h
24 Sugimoto, Y., Inazumi, T. and Tsuchiya, S. (2015) Roles of prostaglandin receptors in female reproduction. J. Biochem. 157, 73–80,
https://doi.org/10.1093/jb/mvu081
25 Prostanoid receptors—G-protein-coupled receptors-UPHAR/BPS Guide to Pharmacology. www.guidetopharmacology.org
26 Matsuoka, T. and Narumiya, S. (2007) Prostaglandin receptor signalling in disease. Sci. World J. 7, 1329–47, https://doi.org/10.1100/tsw.2007.182
27 Bauer, J., Ripperger, A., Frantz, S., Ergun, S., Schwedhelm, E. and Benndorf, R.A. (2014) Pathophysiology of isoprostanes in the cardiovascular
system: implications of isoprostane-mediator thromboxane A2 receptor activation. Brit. J. Pharmacol. 171, 3115–3131,
https://doi.org/10.1111/bph.12677
28 Ye, R.D., Boulay, F., Wang, J.M., Dahlgren, C., Gerard, C., Parmentier, M. et al. (2009) Nomenclature for the formyl peptide receptor (FPR) family.
Pharmacol. Rev. 61, 119–161, https://doi.org/10.1124/pr.109.001578
29 Serhan, C.N., Chiang, N., Dalli, J. and Levy, B.D. (2015) Lipid mediators in the resolution of inflammation. Cold Spring Harb. Perspect. Biol. 4,
a016311, https://doi.org/10.1101/cshperspect.a016311
30 Ravina, E. (2011) The Evolution of Drug Discovery; from traditional medicine to modern drugs, John Wiley, ISBN 978-3-527-32669-3
31 Montinari, M.R., Minelli, S. and De Caterin, R. (2019) The first 3500 years of aspirin history from its roots - A concise summary. Vasc. Pharm. 113,
1–8, https://doi.org/10.1016/j.vph.2018.10.008
32 Limongelli, V., Bonomi, M., Marinelli, L., Gervasio, F.L., Cavalli, A., Novellino, E. et al. (2010) Molecular basis of cyclooxygenase enzumes (COXs)
selective inhibition. Proc. Natl. Acad. Sci., U.S.A. 23, 5411–5416, https://doi.org/10.1073/pnas.0913377107
33 Kurumbail, R.G., Stevens, A.M., Gierse, J.K., McDonald, J.J., Stegeman, R.A., Pak, J.Y. et al. (1996) Structural basis for selective inhibition of
cyclooxygenase-2 by anti-inflammatory agents. Nature 384, 644–648, https://doi.org/10.1038/384644a0
34 Zarghi, A. and Arfaei, S. (2011) Selective COX-2 inhibitors: a review of their structure-activity relationships. Iranian J. Pharm. Res. 10, 655–683
35 Nissen, S.E., Yeomans, N.D., Soloman, D.H. et al. (2016) Cardiovascular safety of celecoxib, naproxen or ibuprofen for arthritis. New Engl. J. Med.
375, 2519–2529, https://doi.org/10.1056/NEJMoa1611593
36 Horn, T., Adel, S., Schumann, R., Sur, S., Kakularam, K.R., Polamarasetty, A. et al. (2015) Evolutionary aspects of lipoxygenases and genetic diversity
of human leukotriene signaling. Prog. Lipid Res. 57, 13–39, https://doi.org/10.1016/j.plipres.2014.11.001
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